SCHEMBL4776669

SCHEMBL4776669

COC(=O)c1ccc(N(Cc2cccc(Cl)c2Cl)S(=O)(=O)CC(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.46
LMNA P02545 3/20 0.46
RAB9A P51151 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 2/20 0.39
ALDH1A1 P00352 2/20 0.38
GRM2 Q14416 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
CYP1A2 P05177 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38
GAA P10253 1/20 0.37
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
HTT P42858 2/20 0.37
KDM4E B2RXH2 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4768135 0.88 MAPT (0.49) MAPTLMNARAB9AL3MBTL1POLB
SCHEMBL4774852 0.85 MAPT (0.47) MAPTLMNARAB9AL3MBTL1POLB
SCHEMBL4777409 0.85 ALDH1A1 (0.51) MAPTLMNARAB9AL3MBTL1POLB
SCHEMBL4767972 0.84 MAPT (0.48) MAPTLMNARAB9AL3MBTL1POLB
SCHEMBL4777497 0.84 MAPT (0.49) MAPTLMNARAB9AL3MBTL1POLB
SCHEMBL4775212 0.83 MAPT (0.48) MAPTLMNARAB9AL3MBTL1POLB
SCHEMBL4767650 0.83 L3MBTL1 (0.49) MAPTLMNARAB9AL3MBTL1POLB
SCHEMBL4776409 0.83 MAPT (0.48) MAPTLMNARAB9AL3MBTL1POLB
SCHEMBL4773537 0.83 MAPT (0.51) MAPTLMNARAB9AL3MBTL1ALDH1A1
SCHEMBL4768002 0.82 MAPT (0.46) MAPTLMNARAB9AL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 MAPT 294/4885LMNA 1022/4885RAB9A 1213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.